182 related articles for article (PubMed ID: 31754835)
1. The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Hu Z; Tian Y; Li W; Ruan Y; Zeng F
Support Care Cancer; 2020 Jul; 28(7):3291-3301. PubMed ID: 31754835
[TBL] [Abstract][Full Text] [Related]
2. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
3. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
4. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Wang Y; Tao H; Yu X; Wang Z; Wang M
Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials.
Mei M; Xiang Z; Yang J; Xiang R
Curr Probl Cancer; 2020 Apr; 44(2):100507. PubMed ID: 31732237
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis.
Chen J; Zhou L; Liu X; Wen X; Li H; Li W
Int J Clin Pharm; 2021 Feb; 43(1):2-10. PubMed ID: 32964403
[TBL] [Abstract][Full Text] [Related]
12. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract][Full Text] [Related]
13. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
14. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
15. Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.
Chen F; Pu F
Oncol Res Treat; 2016; 39(7-8):453-9. PubMed ID: 27487236
[TBL] [Abstract][Full Text] [Related]
16. Role of zoledronic acid in nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis.
Sun XS; Lin C; Liang YJ; Chen QY; Tang LQ; Mai HQ
Oral Oncol; 2019 Oct; 97():31-36. PubMed ID: 31421468
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid combined with chemotherapy in non-small cell lung cancer with bone metastasis.
Zhang J; Wang LYJGJZYPM
J BUON; 2021; 26(3):830-836. PubMed ID: 34268942
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
James ND; Pirrie SJ; Pope AM; Barton D; Andronis L; Goranitis I; Collins S; Daunton A; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Hussain S; Russell M; Billingham LJ
JAMA Oncol; 2016 Apr; 2(4):493-9. PubMed ID: 26794729
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
He M; Fan W; Zhang X
J Hematol Oncol; 2013 Oct; 6(1):80. PubMed ID: 24283946
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis L; Goranitis I; Pirrie S; Pope A; Barton D; Collins S; Daunton A; McLaren D; O'Sullivan JM; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown JE; Chakraborti P; Hussain SA; Russell JM; Billingham LJ; James ND
BJU Int; 2017 Apr; 119(4):522-529. PubMed ID: 27256016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
